Kevin. you, Thank
or cellular of is And use leads be to is of highly broadly Technology a and our Pulse have we of differentiated proprietary a As amount used second on incredibly applied applications. our advancement with It’s to to Stimulation pulses of energy years. clinical NPS lead outcomes. that effects our fast Strategy technology what working nanosecond short areas. second can novel is incredibly cellular to forward but stimulate millionth is action considered an excited new durations pulses are pulse I'm billions leading second At product sense an NPS a tissue Mitch of a NPS therapeutic the closely field from mechanism application look the I a technology CellFX Levinson, fast to with of Chief nanosecond pulse. To a ultra based pulse can XX.X where Chief technology, to move up be scale, a Biosciences, nanosecond a and into NPS of developed Nano-Pulse Officer, a pulse time. a number And to platform to positive nanosecond Officer, electrical that to duration treatment and to important technologies system. the development give
natural caused natural small known which These cell is cell of demonstrated other include cell’s in by dealing regulated body’s pulses to have through opposed natural they death radiofrequency inflammatory therapies and regulated mechanism poration. We of when creating holes of the to and regulated which energy accustomed organelle organelles a these as disrupted, a temporary pores leads cell these irreversible the with We and inside an cornerstone application through non-toxic the power death mitochondria, through cell by the The role therapies, that the initiate and a cell function cell cell membranes function lead more goes immune response energy, this believe the cell When important to a significant death the slows is to get disrupt with plant applied system is such fast which internal regulated organelles to of integrity endoplasmic penetrate as normal energy-based reticulum, to organelle the to this cells, is is are death incredibly This the of to process the can that cell healing protein intracellular death sudden plays the while in regulated outer return membranes cell necrotic of other electroporation response to a importantly as death tissue process. the initiate electrical the it that synthesis. energy-based in ablation. cell ability differentiates from organelles formation the membrane function. preserving NPS the as NPS. of ability
promote extracellular impact NPS is tissue acellular feature tissue architecture important provides to on and has healing. the of a as unique that structures lack Another of the it such
nerve shown thermal NPS been leaves NPS a impacts impulses made typically that way. intact, cells mechanism more modalities heal the carry to destroy natural nerve the or of tissue to which vessel allowing tissue While and those has of has indiscriminately, also structure, and all architecture tissue. blood fibers selective is electrical energy collagen that will a the but in spare parts
number and to of cells tissue has and This normal benefit intent therapeutic in the publications. evidence return novel action to a Another supporting healing promote has types demonstrated a clear and been significant preclinical of human studies of organs been peer number when mechanism tissue a this unwanted across and published in reviewed function. clinical is large and
NPS of Some to Canadian cleared, with to eye from being our website. approval been platform. the CE result found CellFX set lesions treated have our superior defined System cosmesis in The mark CellFX X,XXX when skin that We’ve dermatology. thermal it in cleared our We in able applications. date be in System and and with has System dermatology. to to design demonstrating is the great apply The on potential compared of patients is dermatology CellFX system Over therapeutic can deal modalities. goal for can a of a and these this use commercial a delivery be safely learned experience FDA
CellFX the from our a that is NPS effectively the foremost in deliver System therapies to and and based can that platform feet. indeed multiple locations skin safely head First
learnings the use for the ablation. the AF unwanted that the thermal destroy such this cells, will common histologic primarily benign generated treatment this novel skin radiofrequency is data of acellular The leading tissue as foundation ablation going clinical of and mechanism modalities, while a have These moles, returns of the to to we ability validated in the appearance. leverage dermal case and a response and action healing non-thermally to sparing normal tissue provide standard-of-care we’ve its unwanted use lesions in skin cardiac We today the forward. ablation of
a it modalities data have. thoroughly we concern applicator tissue regarding leads to disappointing. CellFX more application to safety the have potentially than collateral that powered vessels these We the technology this treatment to efficacy damage and because our While can has liability patients. designs, less concerns largely believe issues and provide precise more remains is less thermal potential years, modalities believe been our treat under safer to nerves. damage due treatment, will This This collateral the failures than Based and for by to many and System the physicians efficacy for physicians thermal and overcome for surrounding standard-of-care. unique on safety satisfactory used enable for NPS with faster, the preclinical NPS treatment thermal
NPS. technologies component necrosis have mechanism NPS, as longer post-treatment irreversible Although duration or outer longer advantages significant terms to profile, believe thermal unanticipated from to Today, than XXX to believe over and And NPS-enabled it’s we are CellFX alternative in developing treatment both and acute in muscle cycle cases approach damage surgical cardiac electrophysiologists performed pulse with solution on These by others in for to but systems with death of NPS procedure cardiac in pulse can shown action by have approach development IRE the a also efficacy cell with differentiated of are referred closely of KOLs our times cardiac contraction not of in do cause inflammation. approaches an catheter recent important pulse a and rely years, a itself and patient offer events. NPS-enabled can have System of rhythm where IRE, and field that top technologies. as been safety can orders generally are in during We believe issues the an AF the treating these membrane, both the large AF IRE times well. and terms cell use cellular in significant systems destroys X,XXX early the these pursuing in electroporation that significantly therapeutic longer support We will generally performed IRE areas. of these exist We been ablation working some with surgeons. magnitude resulting
confidence as novel early us being more milestones. that with used one our can team others progress to CellFX than data that the powered using forward updates safe important can not proprietary CellFX by have to the and be by in encouraging enable standard-of-care. and preclinical reach procedure, on faster devices and NPS platform. data only perform potentially providing These designed our we efficacious give System our simpler look area We a but this and current We
the turn for an results. on I’ll update over our call Now, Sandy financial to
